The altered expression profile of microRNAs in cardiopulmonary bypass canine models and the effects of mir-499 on myocardial ischemic reperfusion injury
- Han Qin†1,
- Guang-xian Chen†1,
- Meng-ya Liang†1,
- Jian Rong2,
- Jian-ping Yao1,
- Hai Liu1 and
- Zhong-kai Wu1Email author
© Qin et al.; licensee BioMed Central Ltd. 2013
Received: 31 March 2013
Accepted: 14 June 2013
Published: 21 June 2013
MicroRNAs were enrolled in various cardiovascular disease especially ischemic heart diseases, but the microRNA changes during myocardial ischemia reperfusion injury underwent cardiopulmonary bypass are still unknown. This study screens the microRNA differences in CPB canines and evaluates the relationship of microRNAs with myocardial ischemia reperfusion injury.
13 healthy canines received CPB with 60 minutes of aortic clamping and cardioplegic arrest, followed by 90 minutes reperfusion. Left ventricular myocardial samples, blood samples and hemodynamic data were taken at different time points. We performed microRNAs microarray experiments upon the left ventricle myocardium tissue of canines before CPB and after reperfusion for 90 minutes by pooling 3 tissue samples together and used qRT-PCR for confirmation.
Statistically significant difference was found in mir-499 level before CPB and after reperfusion (T1 vs. T4, p = 0.041). We further examined the mir-499 levels by using qRT-PCR in all 13 canines at 4 different time points (T1 vs. T4, p = 0.029). Mir-499 expression was negatively correlated with cardiac troponin T (cTnT) and creatine kinase- MB (CK-MB) levels of canines in all time points samples (r = 0.469, p < 0.001 and r = 0.273, p = 0.050 respectively). Moreover, higher mir-499 expression level was associated with higher dP/dtmax at 25 minutes and 90 minutes after reperfusion.
Myocardial ischemic reperfusion injury with cardiopulmonary bypass results in declining level of mir-499 expression in left ventricle myocardium of canines, suggesting mir-499 would be a potential therapeutic target in cardiac protection during open heart surgery.
MicroRNAs are short non-coding RNAs which are about 18–25 nucleotides long and act as negative or positive regulators, primarily post-transcriptionally [1, 2]. They have enrolled in various pathological conditions, especially cardiovascular disease , including ischemic heart disease , heart failure , cardiac hypertrophy  and arrhythmias . Recent studies have demonstrated that there are significant expression profile changes in a bunch of microRNAs in both ischemic/normal heart tissues  and peripheral blood . Moreover, some microRNAs perform biological functions of protecting or damaging cardiac cells in myocardial ischemia through different pathways, particularly apoptosis, which brings the treatment potency in the field of microRNAs [4, 10–12].
Recently, the microRNA expression patterns in acute myocardial infarction have been fully elucidated [8, 13]. However, the expression profiles of microRNAs in ischemic reperfusion (IR) injury with CPB are not yet been studied. We hypothesized that there are changes in the level of microRNAs in cardioplegic heart compared to their baseline. Those microRNAs might be potential targets for myocardial protection in CPB. To testify this hypothesis, we analyzed the expression of a broad range of microRNAs using quantitative stem-loop RT-PCR arrays on left ventricular samples at different IR time points in CPB canines, and the clinical relevance of microRNAs with myocardial biochemical markers and hemodynamic changes.
Material and methods
The investigation conforms to the Guide for the Care and Use of Laboratory Animals (NIH publication no. 85–23, revised 1996). All procedures were approved by the Committee on the Ethics of Animal Experiment of the First Affiliated Hospital of Nanjing Medical University (Approval No. 2010CB5295007). All reasonable efforts were made to minimize suffering.
Anesthesia and monitoring
The canines were anesthetized with an intramuscular administration of ketamine (30 mg/kg, JiuXu Pharmaceutical Co. Ltd, Zhejiang, China), fentanyl citrate (2 μg/kg, RenFu Pharmaceutical Co. Ltd, Yi 105 Chang, China), and an intravenous administration of vecuronium bromide (0.1 mg/kg, SiDa Pharmaceutical Co. Ltd, Hainan, China) . Tracheal intubation was performed, and mechanical ventilation was started at a tidal volume of 15 mL/kg body weight 110 and a rate of 15 breaths per minute using a volume cycled respirator (BIRD VELA, Model 606A, USA). The anesthesia was maintained with intravenous infusion of fentanyl, vecuronium bromide, and midazolam. The anesthesia protocol is consistent with the guidance of National Research Council Staff. Fluid-filled catheters were then placed into the left femoral artery for mean arterial pressure (MAP) monitoring and blood sampling. Fluid administration was carried out through cannulation of the left femoral vein. Blood pressure were monitored and recorded by a 16 channel chart recorder (BIOPAC MP150, California, USA).
CPB was performed using one roller pump for extracorporeal circulation and another roller pump for suction. We primed the extracorporeal circuit and the membrane oxygenator (AFFINITY NT 541, Medtronic Inc, USA) with canine blood (average 585 ± 76.97 mL) and multiple electrolyte injections. The total priming volume was approximately 1500 mL. The priming blood was derived from another 13 canines under general anesthesia. Heparin (XinYi Pharmacectic Manufactory of Shanghai Medicine Group, Shanghai) was added to the blood (300U/100 mL) and crystal liquid (200U/100 mL). No other medications were given to minimize any potential cross-reactions. Following preparation, heparin (300U/kg) was given intravenously for systemic anticoagulation. An 18 F arterial perfusion cannula was introduced into the aorta, while two 18 F venous cannulas (Edwards Lifesciences LLC, Irvine, USA) were placed into the right atrium and inferior vena cava, via median sternotomy. After CPB was achieved, cardiac arrest was induced by antegrade injection of homemade cold 4°C crystalloid cardioplegia (10% potassium chloride 7 mL, 25% magnesium sulfate 1.4 mL, 50% glucose 10 mL, 20% mannitol 5 mL, 5% sodium bicarbonate 18 mL, 2% lidocaine 10 mL, and 4 mg dexamethasone, with Ringer’s injection added to a total volume of 500 mL). Electric defibrillation was used if necessary after aortic declamping. Activated clotting time was maintained for more than 480 seconds. The MAP was controlled between 70 and 90 mmHg. The nasopharyngeal temperature was maintained at 36°C by a heat exchanger (Sarns Heater/Cooler, Ann Arbor, MI, USA).
Myocardial biochemical markers determination
At T1, T2, T3, and T4, the blood sample was centrifuged and serum was extracted to measured the levels of cardiac Troponin T (cTnT) and creatine kinase- MB (CK-MB) using a high-sensitivity cardiac troponin T enzyme linked immunosorbent assay kit (USCN Life Science, Wuhan, CHN). Samples of myocardium from left ventricle were obtained using an auto-cardiac biopsy system (Bard MAGNUM REF/Cat.No. MG1522).
Measurement of cardiac function and hemodynamic parameters
A water-filled latex balloon attached to a pressure sensor (model SP844; MEMSCAP Inc., Durham, NC) was inserted into the left ventricle through the left atrium and mitral valve. Blood pressure, maximum left ventricular developed pressure increase (dP/dt max) and decrease rate (dP/dt min) were monitored and recorded at T1, T2, T3 and T4 by a 16-channel chart recorder (BIOPAC MP150, California, 125 USA) .2.7 RNA isolation.
Total RNA was isolated from heart tissue with LCS total RNA extraction kit (TRK-1002) and with this kit genomic DNA contamination can be removed by the process of on column DNase I digestion at room temperature for 15 min, after a series of wash steps the purified total RNA was eluted with elution solution.
For microRNAs microarray analysis, total RNA from 3 left ventricle samples of T1, and 3 samples of T4 (each T1 and T4 is paired to each canines) was isolated. After the isolation, 3 different sample of T1, each 2.5 ug total RNAs were mixed together as a pooling sample, compared with mixed 3 sample of T4. Profiling of miRNAs expression was analyzed by LC Sciences on their microarray platform using Sanger miRBase Release 17.0 database (http://microrna.sanger.ac.uk/sequences/).
The assay started from 10 μg total RNA sample, which was size fractionated using a YM-100 Microcon centrifugal filter (from Millipore) and the small RNAs (< 300 nt) isolated were 3’-extended with a poly(A) tail using poly(A) polymerase. An oligonucleotide tag was then ligated to the poly(A) tail for later fluorescent dye staining; Hybridization was performed overnight on a μParaflo microfluidic chip using a micro-circulation pump (Atactic Technologies) [15, 16]. On the microfluidic chip, each detection probe consisted of a chemically modified nucleotide coding segment complementary to target microRNA (from miRBase, http://microrna.sanger.ac.uk/sequences/) or other RNA (control or customer defined sequences) and a spacer segment of polyethylene glycol to extend the coding segment away from the substrate. The detection probes were made by in situ synthesis using PGR (photogenerated reagent) chemistry. The hybridization melting temperatures were balanced by chemical modifications of the detection probes. Hybridization used 100 μL 6 × SSPE buffer (0.90 M NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formamide at 34°C. After hybridization detection used fluorescence labeling using tag-specific Cy5 dyes. Hybridization images were collected using a laser scanner (GenePix 4000B, Molecular Device) and digitized using Array-Pro image analysis software (Media Cybernetics). Data were analyzed by first subtracting the background and then normalizing the signals using a LOWESS filter  (Locally-weighted Regression). Higher signal indicates higher microRNA expression.
10 microRNAs are selected after microarray analysis and that primers are listed in Tables 1 and 2. For Reverse transcriptase reactions it contained 250 ng total RNA, 1uM stem-loop RT primer, 5× RT buffer,10 mM each dNTPs, 40 U/ul RNase inhibitor and 200 U/ul M-MLV. Reaction mixtures were incubated in an ABI PRISM® 7900HT for 60 min at 42°C, 15 min at 70°C, and held at 4°C. Reverse transcriptase reactions including no-template controls and RT-minus controls were run in duplicate. Real-time PCR was performed using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen). The reaction mixtures were incubated in a 96-well plate at 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 30 sec. All reactions were run in triplicate. To account for possible differences in the amount of starting RNA, microRNA expressions were normalized to small RNU6B, with the similar efficiency of microRNAs [18, 19]. Data of qRT-PCR were demonstrated by nominal CT value (normalized to RNU6B), and fold changes were calculated by 2^|△△CT|. Higher nominal CT value means lower microRNA expression level.
Primers for reverse transcription of microRNAs
Gene Bank/miRbase Access No.
Primers for reverse transcriptase Sequence(5' to 3')
Primers for real time PCR
Forward Primer(5' to 3')
Reversed Primer(5' to 3')
All values are presented as mean ± standard deviation. Results of cardiac enzymes, hemodynamic parameter changes, microarray and qRT-PCR results between time intervals were analyzed by paired t test. Spearman correlation coefficients were used to examine the relationship between miR-499 and cardiac enzymes levels. P < 0.05 was considered statistically significant.
Myocardial biochemical markers changes during cardiopulmonary bypass and reperfusion
MicroRNAs differentially expressed in IR myocardium of canines with CPB and reperfusion by Microarray
Control (T1)/reperfusion (T4)(signals)
Confirmation of the altered expression of microRNAs by qRT-PCR
microRNA differentially expressed in control and after CPB/ reperfusion
Fold Change(T4/T1 )
Mir-499 expression among different time points
Correlation of mir-499 expression and cTnT levels at all time points
Hemodynamic parameters and mir-499 expression level
Association between mir-499 level in T3 and hemodynamic parameters
Mean dP/dtmax with higher mir-499 expression (mmHg)
1107.86 ± 318.10
1116.00 ± 310.10
Mean dP/dtmax with lower mir-499 expression (mHg)
620.67 ± 215.58
629.33 ± 326.55
Mean dP/dtmin with higher mir-499 expression (mmHg)
605.57 ± 369.99
645.29 ± 328.58
Mean dP/dtmin with lower mir-499 expression (mmHg)
360.60 ± 273.99
321.00 ± 256.24
Our study provides evidence that several microRNAs’ level change during myocardial IR injury in CPB canines, which are found in left ventricular myocardiums using microRNA array with pooling samples. Mir-1, mir-494, mir-133, mir-499, mir-214 have been reported to be associated with acute myocardial infarction [8, 11, 13, 20–22]. Some of the altered microRNAs were reported to be related to apoptosis (mir-191 , mir-22 , mir-30 , mir-24 ), hypoxia(mir-451 , mir-23 ) and cell proliferation(mir-489 , let-7e ). These results indicate that a bunch of microRNAs may take part in response to myocardial IR injury. Among aberrantly expressed microRNAs in microarray which were verified by qRT-PCR, mir-499 was found to be a significantly down-regulated microRNA at 90 minutes following reperfusion exclusively. However, the qRT-PCR shows ambivalent results in mir-499 expression compared with results given by microarray. Possible reasons included the disturbance of pooling sample, and the relative inaccuracy of microarray. The present study is the first report to address cardiac microRNAs in a clinical relevant CPB model. Furthermore, there is a moderate negative correlation between mir-499 level, cardiac enzymes levels and hemodynamic parameters, which supports previous studies that mir-499 is in association with cardiomyocytes damage and prognosis. Therefore, our results imply that mir-499 might possibly be a potential therapeutic target of myocardial protection during CPB surgery.
Recently, it was reported that myocardial infarction results in great changes of microRNAs level in myocardium and peripheral blood among patients and animal models [8, 9, 21]. The molecular mechanisms regulating microRNA expression in cardiac ischemia and reperfusion remain largely unknown . However, such pathophysiological conditions closely related to cardiomyocyte apoptosis through which specific microRNAs took roles in preventing and maintaining an effect of cardio-protection . For instance, mir-494 is down regulated in ischaemic hearts and has a cardioprotective effects by activating the Akt pathway . Mir-133 produces opposing effects on apoptosis by targeting heat shock protein 60/70 and caspase-9 in cardiomyocytes . Notwithstanding, most of current studies are base on the model of index heart ischemia mimicking acute coronary syndrome, but the changes in cardiopulmonary bypass still remain uncertain. Recent findings suggest that serum and urine mir-1 act as biomarker of myocardial injury with cardiopulmonary bypass . CPB can trigger apoptosis during cardiac surgery by a series of mechanisms, including ischemia, oxidative stress upon reperfusion, contact with CPB circuit material, proinflammatory cytokines, etc. [35, 36]. Most of the myocardial IR injury in CPB are stunning while myocardial infarction are more common in acute coronary syndrome . Malmberg discovered that short and unprotected warm ischemia produces much more cardiomyocytes apoptosis than a longer period of protected cold ischemia . Thus, current articles about microRNA results in myocardial ischemia can’t be simply utilized in myocardial IR injury of CPB models. Our results demonstrated that among several microRNAs which were found fluctuating following IR injury, only mir-499 was down-regulated. Mir-1, mir-494, mir-133, which shown significant changes in index ischemia [13, 20], can’t demonstrate significant changes during CPB.
Mir-499 is a cardiac ventricular abundant microRNA under physiological condition and evolutionarily conserved among species [38–42]. It is encoded by β-myosin heavy chain gene (Myh7b) [43, 44] and shown a pivotal role in inhibiting cardiomyocytes apoptosis. Researchers noted that mir-499 was down regulated in myocardial ischemia in rats  and correlated to the severity of cardiomyocytes damage . However, our results show that mir-499 fail to decrease after clamping the aorta for 60 minutes. Such phenomenon might origin from the protection effect of hypothermia and cardiaplegic arrest. At 90 minutes after reperfusion, the mir-499 level decrease significantly compared with baseline. This is the first time to demonstrate that mir-499 related to CPB myocardial reperfusion injury, rather than ischemia injury. Furthermore, Mir-499 targets alpha, beta isoforms of the calcineurin catalytic subunit and dynamin-related protein-1 (Drp1) in mitochondria during myocardial infarction , suggesting that mitochondrial activation pathway takes an important role in cardiomyocytic apoptosis after reperfusion in CPB, which is accordance with previous reports .
In the present study, we observed that lower myocardium level of mir-499 was associated with poorer cardiac systolic function during reperfusion than their counterparts. What’s more, mir-499 level in myocardium negatively correlated to cTnT level of peripheral blood, giving a clue that myocardial level of mir-499 might reflect the degree of cardiomyocyte damage. Elevated level of mir-499 in blood of coronary sinus was discovered from patients suffering from troponin-positive acute coronary syndromes and significantly correlated to hsTnT . Moreover, plasma mir-499 was identified as a biomarker and prognostic factor in acute myocardial infarction [47, 48]. Our results confirm and extend the concept of mir-499 in previous reports, showing that the decrease of mir-499 in myocardium might be associated with myocardial injury with a significant release of microRNAs into peripheral circulation.
In principle, the present findings support the hypothesis that microRNAs expression level can be influenced by IR injury in CPB models and IR injury resultes in a decreased level of mir-499 during reperfusion. Lower mir-499 level correlated to more severe IR injury and poor hemodynamic performance. However, the mechanism between microRNAs and IR injury in CPB are not fully understood. Whether the decreased expression level of mir-499 after reperfusion is the cause or the consequence of myocardial injury is still uncertain. We used pooling sample which may diminished the differences for microRNAs array and decrease the sensitivity to examine the unknown microRNAs which participated in IR injury mechanism. Our present study suggested that the introduction of mir-499 as a potential therapeutic method of myocardial protection in open heart surgery would be possible but still wait for further studies.
We would like to acknowledge Dr. Gang Dai and Key Laboratory on Assisted Circulation for experiment assistance.
Source of funding
This work is supported by National Basic Research Program of China (973 Program) (2010CB5295007), Pearl River Scholar Program (80000-3210003) and National Science Fund for Young Scholars (81000061).
- Ambros V: The functions of animal microRNAs. Nature. 2004, 431 (7006): 350-355. 10.1038/nature02871.View ArticlePubMedGoogle Scholar
- Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G: Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med. 2012, 10: 151-10.1186/1479-5876-10-151.PubMed CentralView ArticlePubMedGoogle Scholar
- Callis TE, Wang DZ: Taking microRNAs to heart. Trends Mol Med. 2008, 14 (6): 254-260. 10.1016/j.molmed.2008.03.006.View ArticlePubMedGoogle Scholar
- Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F: MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010, 122 (11 Suppl): S124-S131.PubMed CentralView ArticlePubMedGoogle Scholar
- Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, Jindal HK, Rochira JA, Kunitomo Y, Abdellatif M: MicroRNA-1 and −133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One. 2011, 6 (12): e28324-10.1371/journal.pone.0028324.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang C, Wang S, Zhao P, Wang X, Wang J, Wang Y, Song L, Zou Y, Hui R: MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. J Cell Biochem. 2012, 113 (6): 2040-2046. 10.1002/jcb.24075.View ArticlePubMedGoogle Scholar
- Cooley N, Cowley MJ, Lin RC, Marasco S, Wong C, Kaye DM, Dart AM, Woodcock EA: Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol Genomics. 2012, 44 (3): 211-219. 10.1152/physiolgenomics.00111.2011.View ArticlePubMedGoogle Scholar
- Shi B, Guo Y, Wang J, Gao W: Altered expression of microRNAs in the myocardium of rats with acute myocardial infarction. BMC Cardiovasc Disord. 2010, 10: 11-10.1186/1471-2261-10-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M: Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010, 107 (5): 677-684. 10.1161/CIRCRESAHA.109.215566.View ArticlePubMedGoogle Scholar
- Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA: Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2012, 110 (1): 71-81. 10.1161/CIRCRESAHA.111.244442.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B, Xu C, Zhang B, Zhang F, Dong D: MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res. 2009, 84 (3): 434-441. 10.1093/cvr/cvp232.View ArticlePubMedGoogle Scholar
- Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F: microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther. 2010, 125 (1): 92-104. 10.1016/j.pharmthera.2009.10.003.View ArticlePubMedGoogle Scholar
- Bostjancic E, Zidar N, Stajer D, Glavac D: MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010, 115 (3): 163-169. 10.1159/000268088.View ArticlePubMedGoogle Scholar
- Rong J, Ye S, Wu ZK, Chen GX, Liang MY, Liu H, Zhang JX, Huang WM: Controlled oxygen reperfusion protects the lung against early ischemia-reperfusion injury in cardiopulmonary bypasses by downregulating high mobility group box 1. Exp Lung Res. 2011, 38 (4): 183-191.View ArticleGoogle Scholar
- Gao X, Gulari E, Zhou X: In situ synthesis of oligonucleotide microarrays. Biopolymers. 2004, 73 (5): 579-596. 10.1002/bip.20005.View ArticlePubMedGoogle Scholar
- Zhu Q, Hong A, Sheng N, Zhang X, Matejko A, Jun KY, Srivannavit O, Gulari E, Gao X, Zhou X: microParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol. 2007, 382: 287-312. 10.1007/978-1-59745-304-2_19.View ArticlePubMedGoogle Scholar
- Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19 (2): 185-193. 10.1093/bioinformatics/19.2.185.View ArticlePubMedGoogle Scholar
- Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE: MicroRNA expression in canine mammary cancer. Mamm Genome. 2008, 19 (7–8): 561-569.View ArticlePubMedGoogle Scholar
- Mortarino M, Gioia G, Gelain ME, Albonico F, Roccabianca P, Ferri E, Comazzi S: Identification of suitable endogenous controls and differentially expressed microRNAs in canine fresh-frozen and FFPE lymphoma samples. Leuk Res. 2010, 34 (8): 1070-1077. 10.1016/j.leukres.2009.10.023.View ArticlePubMedGoogle Scholar
- Wang X, Zhang X, Ren XP, Chen J, Liu H, Yang J, Medvedovic M, Hu Z, Fan GC: MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. 2010, 122 (13): 1308-1318. 10.1161/CIRCULATIONAHA.110.964684.PubMed CentralView ArticlePubMedGoogle Scholar
- D‘Alessandra Y, Pompilio G, Capogrossi MC: MicroRNAs and myocardial infarction. Curr Opin Cardiol. 2012, 27 (3): 228-235. 10.1097/HCO.0b013e3283522052.View ArticlePubMedGoogle Scholar
- Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, Li YR, Li PF: miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med. 2011, 17 (1): 71-78. 10.1038/nm.2282.View ArticlePubMedGoogle Scholar
- Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L, Dov A, Marcusson EG, Bennett CF, Chajut A: hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010, 70 (20): 8077-8087. 10.1158/0008-5472.CAN-10-1313.View ArticlePubMedGoogle Scholar
- Xu XD, Song XW, Li Q, Wang GK, Jing Q, Qin YW: Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J Cell Physiol. 2012, 227 (4): 1391-1398. 10.1002/jcp.22852.View ArticlePubMedGoogle Scholar
- Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P: miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010, 6 (1): e1000795-10.1371/journal.pgen.1000795.PubMed CentralView ArticlePubMedGoogle Scholar
- Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D: miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med. 2011, 208 (3): 549-560. 10.1084/jem.20101547.PubMed CentralView ArticlePubMedGoogle Scholar
- Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA, Lawler SE: MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010, 37 (5): 620-632. 10.1016/j.molcel.2010.02.018.PubMed CentralView ArticlePubMedGoogle Scholar
- Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M: A microRNA signature of hypoxia. Mol Cell Biol. 2007, 27 (5): 1859-1867. 10.1128/MCB.01395-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y, Seki N: miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer. 2010, 103 (6): 877-884. 10.1038/sj.bjc.6605811.PubMed CentralView ArticlePubMedGoogle Scholar
- Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, Einvik C: Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011, 105 (2): 296-303. 10.1038/bjc.2011.220.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu H, Fan GC: Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011, 1 (2): 138-149.PubMed CentralPubMedGoogle Scholar
- Yu S, Li G: MicroRNA expression and function in cardiac ischemic injury. J Cardiovasc Transl Res. 2010, 3 (3): 241-245. 10.1007/s12265-010-9168-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, Yang B: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007, 120 (Pt 17): 3045-3052.View ArticlePubMedGoogle Scholar
- Zhou X, Mao A, Wang X, Duan X, Yao Y, Zhang C: Urine and serum microRNA-1 as novel biomarkers for myocardial injury in open-heart surgeries with cardiopulmonary bypass. PLoS One. 2013, 8 (4): e62245-10.1371/journal.pone.0062245.PubMed CentralView ArticlePubMedGoogle Scholar
- Malmberg M, Parkka J, Vahasilta T, Saraste A, Laitio T, Kiss J, Latva-Hirvela J, Saukko P, Savunen T: Cardiomyocyte apoptosis after cardioplegic ischemia: comparison to unprotected regional ischemia-reperfusion. Eur Surg Res. 2011, 46 (1): 19-25. 10.1159/000321875.View ArticlePubMedGoogle Scholar
- Valen G: The basic biology of apoptosis and its implications for cardiac function and viability. Ann Thorac Surg. 2003, 75 (2): S656-S660. 10.1016/S0003-4975(02)04687-8.View ArticlePubMedGoogle Scholar
- Kinoshita T, Asai T: Preservation of myocardium during coronary artery bypass surgery. Curr Cardiol Rep. 2012, 14 (4): 418-423. 10.1007/s11886-012-0271-0.View ArticlePubMedGoogle Scholar
- Kloosterman WP, Steiner FA, Berezikov E, de Bruijn E, van de Belt J, Verheul M, Cuppen E, Plasterk RH: Cloning and expression of new microRNAs from zebrafish. Nucleic Acids Res. 2006, 34 (9): 2558-2569. 10.1093/nar/gkl278.PubMed CentralView ArticlePubMedGoogle Scholar
- Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007, 129 (7): 1401-1414. 10.1016/j.cell.2007.04.040.PubMed CentralView ArticlePubMedGoogle Scholar
- Liang Y, Ridzon D, Wong L, Chen C: Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007, 8: 166-10.1186/1471-2164-8-166.PubMed CentralView ArticlePubMedGoogle Scholar
- Reddy AM, Zheng Y, Jagadeeswaran G, Macmil SL, Graham WB, Roe BA, Desilva U, Zhang W, Sunkar R: Cloning, characterization and expression analysis of porcine microRNAs. BMC Genomics. 2009, 10: 65-10.1186/1471-2164-10-65.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim HJ, Cui XS, Kim EJ, Kim WJ, Kim NH: New porcine microRNA genes found by homology search. Genome. 2006, 49 (10): 1283-1286. 10.1139/g06-120.View ArticlePubMedGoogle Scholar
- van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ, Olson EN: A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell. 2009, 17 (5): 662-673. 10.1016/j.devcel.2009.10.013.PubMed CentralView ArticlePubMedGoogle Scholar
- Yeung F, Chung E, Guess MG, Bell ML, Leinwand LA: Myh7b/miR-499 gene expression is transcriptionally regulated by MRFs and Eos. Nucleic Acids Res. 2012, 40 (15): 7303-7318. 10.1093/nar/gks466.PubMed CentralView ArticlePubMedGoogle Scholar
- De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM: Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011, 124 (18): 1936-1944. 10.1161/CIRCULATIONAHA.111.037572.View ArticlePubMedGoogle Scholar
- Kovacevic M, Simic O, Jonjic N, Stifter S: Apoptosis and cardiopulmonary bypass. J Card Surg. 2007, 22 (2): 129-134. 10.1111/j.1540-8191.2006.00355.x.View ArticlePubMedGoogle Scholar
- Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T: Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011, 51 (5): 872-875. 10.1016/j.yjmcc.2011.07.011.View ArticlePubMedGoogle Scholar
- Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, Nonogi H, Iwai N: Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010, 56 (7): 1183-1185. 10.1373/clinchem.2010.144121.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.